Impact of serum homocysteine on platelet count in stable hemodialysis patients by Nasri, H.
14 The Journal of Applied Research • Vol. 6, No. 1, 2006
KEY WORDS: platelet count,
hemodialysis, end-stage renal failure,
serum homocysteine 
ABSTRACT
Objective: The objective of this study
was to elucidate whether and how the
level of homocysteine as a cause of
hemostatic abnormalities affects platelet
count in hemodialysis patients with 
uremia.
Methods: A cross-sectional study was
conducted on patients with end-stage
renal disease (ESRD) who were under-
going maintenance hemodialysis treat-
ment with acetate basis dialysate and
polysulfone membranes. Serum total
homocysteine (HCY), hemoglobin,
platelet (PLT), and white blood cell
(WBC) counts were measured. Levels of
serum calcium (Ca), phosphorus (P), and
magnesium (Mg) were also measured.
There were 39 study patients (15 female,
24 male) with a mean age of 46 ± 18
years.
Results: The duration of dialysis treat-
ment was 31± 35 months (median, 18
months). The value of serum homocys-
teine for all the patients was 5 ± 2.5
µmol/L (median, 4.5 µmol/L). The mean
PLT count was 155 ± 77 x 103 u/L (medi-
an, 158 x 103 u/L).
Conclusion: This study showed a signifi-
cant positive correlation of PLT count
with serum homocysteine (r=0.35,
P=0.044). In hemodialysis patients high
homocystiene levels make the platelets
more likely to clump and cause clots and
contribute to the possibility of thrombot-
ic events among these patients.
INTRODUCTION
Renal failure has classically been associ-
ated with a bleeding tendency. Thrombo-
tic events are also common among
patients with end-stage renal disease
(ESRD). A variety of thrombosis-favor-
ing hematologic alterations have been
demonstrated in these patients. A non-
traditional risk factor for thrombosis,
such as hyperhomocysteinemia, is pres-
ent in a significant proportion of chronic
dialysis patients. Hemodialysis (HD) vas-
cular access thrombosis and ischemic
heart disease are well-recognized compli-
cations in these patients. Deep venous
thrombosis and pulmonary embolism are
viewed as rare in chronic dialysis
patients, but recent studies suggest that
this perception should be reconsidered.1
Studies have shown that mild-to-moder-
ate elevations in plasma total homocys-
teine (tHcy) levels are observed in the
great majority (>85%) of patients with
ESRD who are undergoing maintenance
dialysis.2
Homocysteine (Hcy) is a non-pro-
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tein, sulfur-containing amino acid that
exists in various forms: a protein-bound
fraction (70% to 80%), a free oxidized
form (20% to 30%), and a free reduced
form (approximately 1%) which recent-
ly has attracted considerable interest as
it may, by several mechanisms, mediate
premature atherosclerosis and cardio-
vascular disease (CVD). Indeed, in the
general population, studies have shown
that even mildly elevated plasma tHcy
levels are associated with an increased
cardiovascular risk.3-5 The mechanism by
which Hcy exerts these effects has yet to
be fully elucidated, although a variety of
possible mechanisms have been pro-
posed, including endothelial dysfunction
or hemostatic abnormalities. Its effects
may be secondary to impaired fibrinoly-
sis or increased platelet reactivity.6
However, the influence of Hcy on
platelets—cells central to the
atherothrombotic process—has never
been addressed directly in studies of
hemodialysis patients.
This study was performed to eluci-
date whether and how the level of
homocysteine as a cause of hemostatic
abnormalities affects the platelet count
in patients with uremia on maintenance
hemodialysis.
PATIENTS AND METHODS
Patients 
This cross-sectional study was conducted
on patients with ESRD who were
undergoing maintenance hemodialysis
treatment with acetate basis dialysate
and polysulfone membranes. The study
was conducted in hemodialysis section
of Hajar Medical, Educational and
Therapeutic Center of Shahrekord
University of Medical Sciences in
Shahrekord, Iran, during July and
August of 2005.
A total of 39 patients (15 female
and 24 male) with a mean age of 46 ± 18
years participated in the study. The
study was carried out in hemodialysis
section of Hajar Medical, Educational
and Therapeutic Center of Shahrekord
University of  Medical Sciences in
Shahrekord  of Iran. The duration of
dialysis treatment was 31 ± 35 months
(median, 18 months). Exclusion criteria
included active or chronic infection and
use of non-steroidal anti-inflammatory
drugs (NSAIDs) or angiotensin-convert-
ing enzyme (ACE) inhibitors or any
other drug known to have adverse effects
on platelet production or function.
According to the severity of second-
ary hyperparathyroidism, each patient
being treated for secondary hyper-
parathyroidism was given oral active
vitamin D3 calcitriol (Rocaltrol; Roche
Laboratories Inc., Nutley, NJ), calcium
carbonate capsule, and sevelamer
(Renagel; Genzyme Europe BV,
Naarden, The Netherlands) tablets at
various doses. According to the severity
of anemia, patients were prescribed
intravenous (IV) iron therapy with Iron
Sucrose (Venofer; International Inc.
St.Gallen, Switzerland) at various doses
after each dialysis session. All patients
received 6 mg of folic acid daily, 500 mg
of Acetyl- L-Carnitine (Jarrow
Formulas, Inc., Los Angeles, CA) daily,
oral vitamin B-complex tablets daily,
and 2,000 U IV recombinant human ery-
thropoietin (Eprex; Janssen-Cilag,
CILAG- AG International Zug,
Switzerland) after each dialysis session.
Table 1 summarizes the patients’
mean age, length of time on hemodialy-
sis, dialysis dosage, and the results of the
laboratory tests.
Laboratory Methods
Blood samples were collected after an
overnight fast. All samples were cen-
trifuged within 15 minutes of venipunc-
ture and serum HCY was measured by
enzyme-linked immunosorbent assay
(ELISA) method using DRG kits (DRG
Diagnostics, Berlin, Germany). The nor-
mal range for serum total homocysteine
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is 25 to 125 µmol/L. In addition, com-
plete blood count containing hemoglo-
bin (Hgb), hematocrit (Hct), platelet
(PLT), and white blood cell (WBC)
count were measured using Sysmex-KX-
21N cell counter (Sysmex Corporation,
Mundelein, IL). Levels of serum calcium
(Ca), phosphorus (P), magnesium (Mg)
were measured using standard methods.
Duration and doses of hemodialysis
treatment were calculated from the
patients’ records. The duration of each
hemodialysis session was 4 hours. For
the efficacy of hemodialysis, the urea
reduction rate (URR) was calculated
from pre- and post-blood urea nitrogen
(BUN) data. Body mass index (BMI)
calculated using the standard formula
(postdialyzed weight in kilograms/height
in meters squared; kg/m2).
Statistical Analysis
Results are expressed as the mean ±
standard deviation (SD) and median
values. Statistical correlations were
assessed using a partial correlation test.
All statistical analyses were performed
using SPSS version 11.00 (SPSS Inc.
Chicago, IL). Statistical significance was
defined as P<0.05.
RESULTS
The value of serum homocysteine for all
patients was 5 ± 2.5 µmol/L (median, 4.5
µmol/L). The mean PLT count was 155 ±
77 x 103u/L (median, 158 x 103u/L). In
this study a significant positive correla-
tion of PLT count with serum homocys-
teine (r=0.35, P=0.044) adjusted for age,
duration and doses of dialysis, WBC
count, serum Mg was seen (Figure 1).
DISCUSSION
In this study, a significant positive corre-
lation of PLT count with serum homo-
cysteine was found. Recent evidence
indicates that hyperhomocysteinemia is
an independent risk factor for athero-
sclerosis, thrombosis, and other cardio-
vascular diseases. This may be secondary
to impaired fibrinolysis or increased
platelet reactivity. Nitric oxide (NO), a
Table 1. Mean ± standard deviation (SD) and median values of age, duration, and doses of
hemodialysis as well as laboratory results for all patients.
Total patients (n=39) Mean ± SD Median
Age (years) 46 ± 18 42
Duration of hemodialysis  (months) 31 ± 35 18
Dialysis 280 ± 381 156
dose (sessions)
URR % 58.7 ± 8.7 58
Ca (mg/dL) 7.7 ± 1 8
Hgb (g/dL) 9 ± 2 9
HCT % 28 ± 6 29
Homocysteine (µmol/L) 5 ± 2.5 4.5
Mg (mg/dL) 2.5 ± 04 2.4
P (mg/dL) 6.4 ± 1.9 6.4
WBC count 5864 ± 1922 5500
(cells/mm3)
PLT count (x 103u/L) 155 ± 77 158
URR= urea reduction rate; Ca=serum calcium; Hgb=hemoglobin; HCT= hematocrit; Mg= magnesium; 
P= phosphorus;WCB=white blood cell; PLT=platelet
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product from L-arginine by nitric oxide
system (NOS) and potent anti-aggregat-
ing agent, plays an important role in the
regulation of platelet function. The
results of a study conducted by Leoncini
et al indicate that the L-arginine/NO
pathway is one of the various targets of
homocysteine in human platelets. The
increased Ca2+ levels associated with
reduced NO formation may generate
hyperactivation and may contribute to
the thrombogenic processes.6
The pathogenic mechanism of ather-
osclerosis and thrombosis caused by
homocysteine has not been fully clari-
fied, but oxygen-free species produced
by the homocysteine metabolism and
auto-oxidation could play a role.7 To
study the effect of homocysteine on
arachidonic acid release in human
platelets, Signorello et al showed that
homocysteine induces oxidative stress in
human platelets in vitro.7 The unbalance
in platelet redox-state and the increased
thromboxane B2 (TXB2) formation may
generate hyperactivation, contributing to
a thrombogenic state leading to cardio-
vascular diseases.7
It is thought that L-arginine/nitric
oxide synthase/nitric oxide plays an
important role in the regulation of
platelet function.8 Li et al showed that
that the L-arginine/NO pathway is
involved in the mechanism responsible
for the effects of HCY on platelets by
diminishing NO production through
decreased uptake of L-arginine and the
resulting increased platelet reactivity.8
In this regard, Mutus, in a study which
included 28 patients with Type I (insulin-
dependent) diabetes mellitus, 30 patients
with Type II (non-insulin-dependent)
diabetes mellitus, and 34 healthy sub-
jects, showed that basal platelet NO pro-
duction was lower in diabetic patients
than in healthy subjects. NO release was
reduced by in vitro homocysteine incu-
bation, being lower in platelets from dia-
betic patients than in platelets from
control subjects.9 They concluded that
homocysteine could exert its athero-
genic action in healthy and diabetic sub-
jects partly by inhibiting platelet nitric
oxide production with the subsequent
Figure 1. Significant positive correlation of platelet (PLT) count with serum homocysteine
(r=0.35, P=0.044), adjusted for age, duration and doses of dialysis, white blood cell count (WBC),
serum magnesium (Mg).
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increased platelet activation and 
aggregation.9
Using a rat model, Duranp et al
showed that dietary folic acid deficiency,
a major cause of basal hyperhomocys-
teinemia, is associated with enhanced
macrophage-derived tissue factor and
platelet activities.10 They proposed that a
homocysteine-induced oxidative stress
may account for this hypercoagulable
state. They concluded that moderate
hyperhomocysteinemia plays a role in
the development of a thrombogenic
state that might be mediated by the
occurrence of oxidative stress.10
Studies in the general population
suggest that low-grade inflammation,
endothelial dysfunction, and platelet
activation are associated with an
increased risk of cardiovascular events.10
Landray et al attempted to asses the
markers of inflammation, endothelial
dysfunction, and platelet activation in
334 patients with chronic kidney disease
compared to two age- and sex-matched
control groups, one comprised of 92
patients with coronary artery disease
and the other comprised of 96 apparent-
ly healthy individuals with no history of
cardiovascular or kidney disease.11 They
found that chronic kidney disease is
associated with low-grade inflammation,
endothelial dysfunction, and platelet
activation, even among patients with
moderate renal impairment.11
In hemodialysis patients, folate defi-
ciency and resultant hyperhomocysteine-
mia are commonly seen.12 Our result
show that, in hemodialysis patients,
serum HCY had a positive correlation
with PLT count that could explain some
thrombotic events among patients with
ESRD. The above-mentioned studies
regarding the mechanisms for increased
PLT activities through hyperhomocys-
teinemia may also exist in ESRD
patients, therefore our conclusion indi-
cate a need for greater attention to this
issue in hemodialysis patients. They also
showed that more study is needed on
the effects of serum HCY on PLT func-
tion in ESRD patients.
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